← Back to Search

Atezolizumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until 90 days after end of treatment (approximately 16.5 months overall)
Awards & highlights

Study Summary

This trial was designed to see if the immunotherapy drug atezolizumab is safe and effective in treating Non-Small Cell Lung Cancer. The study gave atezolizumab to patients before and after surgery, and then monitored them for up to 3 years.

Who is the study for?
This trial is for people with a certain stage of lung cancer (Stage IB, II, IIIA, or some IIIB). They must be physically able to handle the treatments and have not had any lung cancer therapy in the last 3 years. People with specific advanced cancers, prior PD-1 or PD-L1 therapies, or autoimmune diseases can't join.Check my eligibility
What is being tested?
The study tests Atezolizumab as an initial (neoadjuvant) and follow-up (adjuvant) treatment for those who can surgically remove their lung cancer. It involves two cycles before surgery and up to a year of treatment after if it helps initially. Patients are followed for disease recurrence and survival for three years.See study design
What are the potential side effects?
Atezolizumab may cause immune-related side effects like inflammation in various organs, infusion reactions similar to allergic responses during administration, fatigue, potential liver issues, skin problems like rash or itching.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until 90 days after end of treatment (approximately 16.5 months overall)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline until 90 days after end of treatment (approximately 16.5 months overall) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Major Pathologic Response (MPR)
Secondary outcome measures
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Percentage of Participants With Adverse Events
Percentage of Participants With Major Pathologic Response Rates For Programmed Death Ligand 1 (PD-L1)-Positive Versus PD-L1-Negative Participants

Side effects data

From 2023 Phase 3 trial • 453 Patients • NCT03191786
22%
Decreased appetite
20%
Cough
19%
Fatigue
18%
Dyspnoea
16%
Constipation
16%
Anaemia
14%
Asthenia
13%
Diarrhoea
11%
Pneumonia
11%
Nausea
10%
Pyrexia
10%
Rash
10%
Urinary tract infection
9%
Arthralgia
8%
Back pain
8%
Hyponatraemia
8%
Vomiting
8%
Oedema peripheral
8%
Pruritus
7%
Hypertension
7%
Weight decreased
6%
Hypokalaemia
6%
Haemoptysis
6%
Hypothyroidism
6%
Insomnia
5%
Headache
5%
Blood creatinine increased
5%
Dizziness
4%
Pain in extremity
3%
Pleural effusion
3%
Pneumonitis
2%
Lower respiratory tract infection
2%
Death
2%
Infective exacerbation of chronic obstructive airways disease
2%
Chronic obstructive pulmonary disease
1%
Immune-mediated hepatitis
1%
Syncope
1%
Acute myocardial infarction
1%
Leukopenia
1%
Neutropenia
1%
Diabetic ketoacidosis
1%
Respiratory tract infection
1%
Septic shock
1%
Cardiac failure
1%
Hyperglycaemia
1%
Sudden cardiac death
1%
Atrial fibrillation
1%
Upper respiratory tract infection
1%
Fall
1%
Femoral neck fracture
1%
Femur fracture
1%
Acute kidney injury
1%
White blood cell count decreased
1%
Cellulitis
1%
Bronchitis
1%
Pneumonia aspiration
1%
Pneumothorax
1%
Pulmonary embolism
1%
Deep vein thrombosis
1%
Hypercalcaemia
1%
Confusional state
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab
Single Agent Chemotherapy (Vinorelbine or Gemcitabine)

Trial Design

1Treatment groups
Experimental Treatment
Group I: AtezolizumabExperimental Treatment1 Intervention
Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
FDA approved

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,539 Previous Clinical Trials
567,508 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,199 Previous Clinical Trials
888,321 Total Patients Enrolled

Media Library

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Clinical Trial Eligibility Overview. Trial Name: NCT02927301 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: Atezolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Highlights & Side Effects. Trial Name: NCT02927301 — Phase 2
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody 2023 Treatment Timeline for Medical Study. Trial Name: NCT02927301 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At how many different research facilities can patients participate in this study?

"Currently, this clinical trial has 21 sites recruiting patients. Some of these locations include University Of Colorado in Aurora, Mass General/North Shore Cancer in Danvers, Moffitt Cancer Center in Tampa and other medical centres."

Answered by AI

Does this research differ significantly from other similar investigations?

"Atezolizumab (MPDL3280A) is an engineered anti-PD-L1 antibody that has been studied in 356 live clinical trials across 1665 cities and 74 countries. The earliest trial for Atezolizumab occurred in 2008 and was sponsored by Hoffmann-La Roche. This trial involved 720 patients and completed its Phase 2 drug approval stage. Since 2008, 79 studies have been completed."

Answered by AI

What is the extent of research on Atezolizumab (MPDL3280A), an antibody designed to target PD-L1?

"Atezolizumab (MPDL3280A) is an antibody that was originally studied in 2008 at Illinois Cancer Care. As of right now, 79 studies have been completed and 356 trials are ongoing. Many of these active trials are taking place in Aurora, Colorado."

Answered by AI

How many individuals are being given this opportunity to participate in this trial?

"This study is not currently looking for more participants. It was originally posted on April 20th, 2017 and last updated on September 28th, 2022. That being said, there are presently 2098 trials actively searching for participants with non-small cell lung carcinoma (nsclc) and 356 studies for Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody admitting patients."

Answered by AI

Is this research study recruiting new participants at this time?

"This study, as recorded on clinicaltrials.gov, is not looking for any more participants at the moment. The original posting was on April 20th 2017 and the most recent edit was on September 28th 2022. There are 2454 other trials that are currently recruiting patients right now though."

Answered by AI

What has Atezolizumab been shown to be an effective treatment for?

"Atezolizumab, an antibody that targets the protein PD-L1, is frequently used to treat patients with small cell lung cancer. However, it has also been proven effective against several other conditions such as non-small cell lung carcinoma and postoperative malignant neoplasms."

Answered by AI

Are there any safety concerns with Atezolizumab (MPDL3280A)?

"Atezolizumab (MPDL3280A) is an antibody that has gone through some engineering in order to target PD-L1. As this medication is still in Phase 2 of clinical trials, there is not yet efficacy data supporting its use. However, there are safety studies indicating that it merits a score of 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
2017. "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02927301.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top